- Symrise invests in Cellibre to enhance fermentation-derived ingredient production.
- The partnership focuses on taste solutions and cosmetic actives.
- Cellibre specializes in sustainable biomanufacturing and microorganism engineering.
- The collaboration aims to improve supply chain resilience and sustainability.
Investment Overview
Symrise has made a strategic equity investment in Cellibre, a U.S.-based biotechnology company. This move aims to advance innovation in fermentation-derived ingredients for taste solutions and cosmetic actives.
Technology Access
Through this partnership, Symrise gains preferred access to Cellibre's proprietary fermentation-based technology. This enables scalable production of high-value ingredients across various sectors, including food, beverage, cosmetics, and nutraceuticals.
Supply Chain Resilience
The collaboration is designed to enhance supply chain resilience by mitigating seasonal and cultivation variability. Symrise will leverage Cellibre’s biotechnology platform to achieve this goal.
Cellibre's Expertise
Cellibre has a strong track record in designing and engineering microorganisms for producing cultured natural products and chemicals. These are used in pharmaceuticals, functional health, beauty ingredients, and industrial applications.
Strategic Alignment
This partnership aligns with Symrise’s ambition to integrate biotechnology across its operations, ensuring long-term resilience and competitive advantage. It also supports the company's sustainability commitments and consumer-driven innovation strategy.
